The aim of the work is to present our experiences with the evaluation of the effect of RFA (radiofrequency ablation) of liver and kidney using ultrasound contrast agent SonoVue (Bracco, Italy) and the comparison with other imaging modalities, that are used fot the evaluation of the effect of the therapy – CT, US, MRI PET and PET-CT.